Dendritic cell based cancer vaccine

Research Aim: Long term goal of the group of tumor immunotherapy is the development of dendritic cell based cancer vaccine. Administration of this vaccine should induce tumor cell-specific induce response and contribute to current treatment options.
This project was completed in March 2014, when two clinical studies aimed on treatment of prostate cancer and ovarian cancer were finished in University hospital Motol. Dendritic cell biology and their use in the immunotherapy of tumors have been studied at the Institute of Immunology for more than 10 years as documented by the list of publications. Further development and production of dendritic cells based vaccines was taken over by biotechnological company SOTIO.

Principal Investigators prof. Jiřina Bartůňková, M.D., Ph.D., MBA., Radek Špíšek, M.D., Ph.D.

Financial support: Research of dendritic cells at the Institute of Immunology, Charles University, 2nd Medical School has been supported by grants from Ministry of Education, grant agencies, grants form European Union.

Created: 12. 6. 2019 / Modified: 17. 6. 2019 / Responsible person: RNDr. Jan Lašťovička, CSc.